1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

A Competitive Analysis of the Global Breast Cancer Therapeutics Market : A New Class of Targeted Therapeutics Offers Novel Treatment Modalities to Treat Difficult Breast Cancers

  • 68 pages, published in March 2015
  • By Frost & Sullivan
  • Report Number: 2779417


Table of Contents

Executive Summary

•The global breast cancer therapeutics market is divided into x segments: hormonal therapy, targeted therapy, chemotherapy, and other therapy (for example, novel drugs in development).
•About x hormonal therapies are available to treat breast cancer. The most common ones are aromatase inhibitors and selective oestrogen receptor modulators (SERMs).
•Only x approved targeted treatments are available in the U.S. market, namely, Herceptin (Roche) and Tykerb (GSK). 2 more drugs, Kadcyla (Roche) and Perjeta (Roche), were approved in 2013. At present, Roche dominates the global breast cancer therapeutics market.
•Although there are approximately x drugs indicated for the treatment of breast cancer, there remains a large unmet need to treat patients. As a result, the breast cancer pharmaceutical pipeline is strong, with about x drugs in development.
•Chemotherapy remains the most important class of drugs for breast cancer treatment; however, the trend of using targeted drugs is on the rise.
•Combination treatment is a focus for companies with breast cancer treatment in development; however, drugs that held potential in Phase 2 trials failed to make an impact in Phase 3, forcing companies to re-design trials or stop the research programme.
•Between 2015 and 2017, the key drugs to watch out for will be ABT-888 (AbbVie), NeuVax (Galena Biopharma), Palbociclib (Pfizer), NKTR-102 (Nektar), Nexavar (Bayer/Onyx), and CT-P6 (Celltrion).
•Palbocilib (Pfizer), LY2835219 (Eli Lilly), and LEE011(Novartis) are the most exciting drugs to look out for as they represent the cyclin-dependent kinases (CDK) unique class of drug inhibitors, a first of a kind from a breast cancer therapeutics perspective.
•Palbocilib is a CDK inhibitor oral drug that has been approved for filing and granted priority review by the U.S. Food and Drug Administration (FDA). If approved, this treatment will benefit patients as a first-line therapy (in combination with letrozole).
•LY2835219 (Eli Lilly) and LEE011 (Novartis) are the other key CDK inhibitors expected to compete with Palbocilib. Although no preliminary data is available in terms of Phase 3 trials, at present, they are anticipated with positive enthusiasm from their developers.
•In 2014, market size was estimated at $ x billion; the market is expected to witness a compound annual growth rate (CAGR) of x % over the next x years.

Physician Guidelines to Breast Cancer Therapy—Her 2 Positive

•Herceptin therapy, along with chemotherapy combination, such as Xeloda and Tykerb, represents the standard treatment regime for Her 2-positive breast cancer.
•This standard treatment is also being administered subcutaneously to reduce run time. Most breast cancer patients benefit from this therapy, demonstrating an affirmative response to Her 2 positive.
•New versions, such as Kadcyla and Perjeta, leverage Roche’s proprietary technology.

Physician Guidelines to Breast Cancer Therapy—ER or PR Positive

•Hormone-positive patients represent the next largest market and are usually treated with Faslodex, along with chemotherapeutic agents, such as anthracyclines or taxanes.
• Exemestane is usually prescribed after the failure of Tamoxifen. It also serves as a third-line therapy option for advanced breast cancer patients.

Physician Guidelines to Breast Cancer Therapy— Triple-negative Breast Cancer

•Ideally, anthracyclin or taxane is administered to patients with triple-negative breast cancer as they do not respond to either hormone therapy or Her 2-positive-targeted therapeutics.
•At present, new and promising therapeutic targets, such as CDKs, poly-adenosine ribose phosphates, and epidermal growth factor receptors are being evaluated to develop drugs to fulfil this unmet need.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you get this report now


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Crohn’s Disease Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Crohn’s disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of ...

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • February 2017
  • by GlobalData

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. ...

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Hormone and Therapy Market in Pakistan and the US

  • May 2017
    7 pages
  • Hormone  



  • Pakistan  

    United States  

View report >

Antipsychotic Market and Psychotic Disorder Statistics in Europe

  • May 2017
    2 pages
  • Antipsychotic  


    Psychotic Disor...  

  • Europe  



View report >

Therapy Market in the Netherlands

  • May 2017
    9 pages
  • Therapy  


  • Netherlands  

View report >

Related Market Segments :

Breast Cancer


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.